KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF‑β/SMAD signaling pathway

Li,Yuan; Yang,Jing; Zhang,Xin; Liu,Hong; Guo,Jin

doi:10.3892/etm.2020.9000

KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF‑β/SMAD signaling pathway

Authors:
- Yuan Li
- Jing Yang
- Xin Zhang
- Hong Liu
- Jin Guo
View Affiliations

Affiliations: Department of General Surgery, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China
Published online on: July 13, 2020 https://doi.org/10.3892/etm.2020.9000
Pages: 2774-2782
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lysine demethylase 6A (KDM6A) is a Jumonji‑C domain‑containing histone demethylase that specifically catalyzes the removal of histone H3 lysine‑27 trimethylation. KDM6A is a member of the KDM6 family, the biological role of which has been reported in various types of cancer, including bladder and lung cancer, as well as pancreatic ductal adenocarcinoma. However, the role of KDM6A in hepatocellular carcinoma (HCC) is not completely understood. Therefore, the present study aimed to determine the biological function of KDM6A in HCC progression. The expression profile of KDM6A was examined in HCC surgical specimens using reverse transcription‑quantitative PCR. In addition, the role of KDM6A in the proliferation capacities of HCC cell lines was examined in vitro and in vivo using crystal violet and MTT assays. The underlying mechanism by which KDM6A exerts its function was explored by western blotting. The present study indicated that KDM6A was significantly downregulated in HCC tissues compared with normal control tissues. The role of KDM6A in HCC cell proliferation was also determined. KDM6A overexpression significantly inhibited HCC cell proliferation, whereas KDM6A knockdown significantly promoted HCC cell proliferation compared with the corresponding control groups. Consistently, KDM6A overexpression suppressed HCC cell tumorigenesis in vivo. The western blotting results indicated that KDM6A overexpression decreased the phosphorylation levels of smad2, whereas KDM6A knockdown increased the phosphorylation levels of smad2 compared with the corresponding control groups. Therefore, the present study suggested that KDM6A may inhibit HCC cell proliferation by negatively regulating the TGF‑β/SMAD signaling pathway, suggesting that KDM6A may serve as a potential target for the diagnosis and treatment of HCC.

View Figures

View References

1	European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 69:182–236. 2018.PubMed/NCBI View Article : Google Scholar
2	Lu XJ, Shi Y, Chen JL and Ma S: Krüppel-like factors in hepatocellular carcinoma. Tumour Biol. 36:533–541. 2015.PubMed/NCBI View Article : Google Scholar
3	Yu WB, Rao A, Vu V, Xu L, Rao JY and Wu JX: Management of centrally located hepatocellular carcinoma: Update 2016. World J Hepatol. 9:627–634. 2017.PubMed/NCBI View Article : Google Scholar
4	Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA and Giulini SM: Early and late recurrence after liver resection for hepatocellular carcinoma: Prognostic and therapeutic implications. Ann Surgery. 243:229–235. 2006.PubMed/NCBI View Article : Google Scholar
5	Hu J and Gao DZ: Distinction immune genes of hepatitis-induced heptatocellular carcinoma. Bioinformatics. 28:3191–3194. 2012.PubMed/NCBI View Article : Google Scholar
6	Marquardt JU, Galle PR and Teufel A: Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. J Hepatol. 56:267–275. 2012.PubMed/NCBI View Article : Google Scholar
7	Hong S, Cho YW, Yu LR, Yu H, Veenstra TD and Ge K: Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad Sci USA. 104:18439–18444. 2007.PubMed/NCBI View Article : Google Scholar
8	Lee MG, Villa R, Trojer P, Norman J, Yan KP, Reinberg D, Di Croce L and Shiekhattar R: Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science. 318:447–450. 2007.PubMed/NCBI View Article : Google Scholar
9	Jiang W, Wang J and Zhang Y: Histone H3K27me3 demethylases KDM6A and KDM6B modulate definitive endoderm differentiation from human ESCs by regulating WNT signaling pathway. Cell Res. 23:122–130. 2013.PubMed/NCBI View Article : Google Scholar
10	Schuettengruber B, Bourbon HM, Di Croce L and Cavalli G: Genome Regulation by Polycomb and Trithorax: 70 Years and Counting. Cell. 171:34–57. 2017.PubMed/NCBI View Article : Google Scholar
11	van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, et al: Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet. 41:521–523. 2009.PubMed/NCBI View Article : Google Scholar
12	Terashima M, Ishimura A, Yoshida M, Suzuki Y, Sugano S and Suzuki T: The tumor suppressor Rb and its related Rbl2 genes are regulated by Utx histone demethylase. Biochem Biophys Res Commun. 399:238–244. 2010.PubMed/NCBI View Article : Google Scholar
13	Watanabe S, Shimada S, Akiyama Y, Ishikawa Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, et al: Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. Int J Cancer. 145:192–205. 2019.PubMed/NCBI View Article : Google Scholar
14	Ler LD, Ghosh S, Chai X, Thike AA, Heng HL, Siew EY, Dey S, Koh LK, Lim JQ, Lim WK, et al: Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci Transl Med. 9(eaai8312)2017.PubMed/NCBI View Article : Google Scholar
15	Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W and Tzatsos A: Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors. Cancer Cell. 33:512–526.e8. 2018.PubMed/NCBI View Article : Google Scholar
16	Terashima M, Ishimura A, Wanna-Udom S and Suzuki T: Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells. Biochem Biophys Res Commun. 490:1407–1413. 2017.PubMed/NCBI View Article : Google Scholar
17	Wang Y, Liu DP, Chen PP, Koeffler HP, Tong XJ and Xie D: Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res. 67:2535–2543. 2007.PubMed/NCBI View Article : Google Scholar
18	Qiu Z, Zou K, Zhuang L, Qin J, Li H, Li C, Zhang Z, Chen X, Cen J, Meng Z, et al: Hepatocellular carcinoma cell lines retain the genomic and transcriptomic landscapes of primary human cancers. Sci Rep. 6(27411)2016.PubMed/NCBI View Article : Google Scholar
19	Vatandoost J and Kafi Sani K: A study of recombinant factor IX in Drosophila insect S2 cell lines through transient gene expression technology. Avicenna J Med Biotechnol. 10:265–268. 2018.PubMed/NCBI
20	Sikes RS: 2016 Guidelines of the American Society of Mammalogists for the use of wild mammals in research and education. J Mammal. 97:663–688. 2016.PubMed/NCBI View Article : Google Scholar
21	Zha L, Cao Q, Cui X, Li F, Liang H, Xue B and Shi H: Epigenetic regulation of E-cadherin expression by the histone demethylase UTX in colon cancer cells. Med Oncol. 33(21)2016.PubMed/NCBI View Article : Google Scholar
22	Choi HJ, Park JH, Park M, Won HY, Joo HS, Lee CH, Lee JY and Kong G: UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1. EMBO Rep. 16:1288–1298. 2015.PubMed/NCBI View Article : Google Scholar
23	Dai J, Xu M, Zhang X, Niu Q, Hu Y, Li Y and Li S: Bi-directional regulation of TGF-β/Smad pathway by arsenic: A systemic review and meta-analysis of in vivo and in vitro studies. Life Sci. 220:92–105. 2019.PubMed/NCBI View Article : Google Scholar
24	Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003.PubMed/NCBI View Article : Google Scholar
25	Wrana JL, Attisano L, Wieser R, Ventura F and Massagué J: Mechanism of activation of the TGF-beta receptor. Nature. 370:341–347. 1994.PubMed/NCBI View Article : Google Scholar
26	Moses HL, Roberts AB and Derynck R: The discovery and early days of TGF-β: A historical perspective. Cold Spring Harb Perspect Biol. 8(a021865)2016.PubMed/NCBI View Article : Google Scholar
27	Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 29:117–129. 2001.PubMed/NCBI View Article : Google Scholar
28	Pasche B: Role of transforming growth factor beta in cancer. J Cell Physiol. 186:153–168. 2001.PubMed/NCBI View Article : Google Scholar
29	Elliott RL and Blobe GC: Role of transforming growth factor Beta in human cancer. J Clin Oncol. 23:2078–2093. 2005.PubMed/NCBI View Article : Google Scholar